RARA and acute promyelocytic leukemia: The purpose of this study was to determine the effect of 3-Deazaneplanocin A and Belinostat in combination with conventional treatment (RA + Idarubicin) on NB4 and HL60 cells in vitro and on APL patient promyelocytes possessing PML-RARA translocation ex vivo.